Medtronic PLC $MDT Shares Acquired by Smartleaf Asset Management LLC

Smartleaf Asset Management LLC increased its stake in Medtronic PLC (NYSE:MDT) by 36.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,275 shares of the medical technology company’s stock after buying an additional 5,105 shares during the period. Smartleaf Asset Management LLC’s holdings in Medtronic were worth $1,811,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Corundum Trust Company INC bought a new position in Medtronic during the 3rd quarter worth approximately $27,000. Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic during the 3rd quarter valued at approximately $29,000. Delos Wealth Advisors LLC bought a new position in Medtronic during the second quarter worth $27,000. Steigerwald Gordon & Koch Inc. acquired a new position in Medtronic in the third quarter worth $33,000. Finally, Tripletail Wealth Management LLC acquired a new position in Medtronic in the third quarter worth $34,000. 82.06% of the stock is currently owned by institutional investors.

Medtronic Stock Performance

Shares of NYSE MDT opened at $102.89 on Monday. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The company has a market cap of $131.91 billion, a PE ratio of 27.73, a P/E/G ratio of 2.71 and a beta of 0.71. The stock has a 50 day simple moving average of $99.40 and a 200-day simple moving average of $96.16. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the previous year, the business earned $1.26 EPS. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on MDT. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Robert W. Baird set a $103.00 target price on shares of Medtronic in a report on Tuesday, December 16th. Truist Financial decreased their target price on Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a research note on Thursday, December 18th. Wells Fargo & Company assumed coverage on Medtronic in a research report on Friday, January 30th. They set an “overweight” rating and a $114.00 price target on the stock. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $110.67.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).